| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1388-9842(01)00159-3 |
| P698 | PubMed publication ID | 11595612 |
| P2093 | author name string | Steinbach M | |
| Opitz C | |||
| Kleber FX | |||
| Wruck U | |||
| Gläser S | |||
| P2860 | cites work | The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology | Q33989507 |
| Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist | Q41587071 | ||
| Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. | Q50936529 | ||
| Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group | Q71235691 | ||
| Effects of mibefradil on intracellular Ca2+ release in cultured rat cardiac fibroblasts and human platelets | Q71377756 | ||
| Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension | Q73538268 | ||
| Mibefradil: a new class of calcium-channel antagonists | Q74701160 | ||
| P433 | issue | 5 | |
| P921 | main subject | torsades de pointes | Q1625433 |
| P304 | page(s) | 627-630 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | European Journal of Heart Failure | Q5017954 |
| P1476 | title | Torsades de pointes caused by Mibefradil | |
| P478 | volume | 3 |
| Q53207586 | CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical |
| Q37385343 | Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation |
| Q35892164 | Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. |
| Q24803870 | Equivalence and noninferiority trials - are they viable alternatives for registration of new drugs? (III) |
| Q74248344 | Pharmacoepidemiology and drug safety |
| Q36926861 | Regulation of aldosterone secretion by Cav1.3. |
| Q46643053 | The Ca(2+) channel inhibitor efonidipine decreases voltage-dependent K(+) channel activity in rabbit coronary arterial smooth muscle cells |
Search more.